Gerovital H3 is the drug developed by Professor Dr. Ana Aslan in collaboration with pharmacist Elena Polovrageanu, based on observations at that time on the effects of procaine. Professor Daniel Danielopolu, who played an essential role in the creation of the Institute of Physiology, noted that procaine “restores and increases active vital processes and local resistance”, and Professor Dr. Ana Aslan intuited and discovered the biotrophic therapeutic actions of procaine, through long-term treatment in small doses, with a curative and prophylactic role.
The best known and studied effects of Gerovital H3 are the antioxidant and antidepressant effects.
Gerovital H3, through its active ingredient – procaine, but also through its other ingredients (potassium metabisulfite, benzoic acid) exerts antioxidant action through several mechanisms, including direct inhibition of free radical generation and limitation of lipid peroxidation reactions of cell membranes.
Numerous studies have confirmed the role of procaine and Gerovital H3 as protective agents against oxidative stress: this role could explain the antiatherogenic effect and slowing down the effects of aging.
Chronic treatment with Gerovital H3 has antiatherosclerotic effects, a consequence of the reduction of cholesterol mobilized from deposits and of the lipotropic action, especially through its primary metabolite, diethylaminoethanol (DEAE).
Studies have also confirmed the “statin-like” action of procaine, exerted by regulating the activity of HMG-CoA-reductase, involved in cholesterol biosynthesis, with a decrease in total cholesterol and an increase in HDL cholesterol.
The antidepressant effect is exerted because Gerovital H3 is a weak, reversible and competitive monoamine oxidase inhibitor (MAOI) (which gives it reduced side effects compared to other MAOIs).
Other clinically proven effects are:
Reducing pain and improving mobility in patients with joint diseases, especially arthritic ones
Reducing stiffness and hypokinesia in syndromes and Parkinson's disease
Through all these beneficial effects, as well as through its use for more than 60 years, Gerovital H3 has proven its usefulness in the prevention and prophylaxis of some of the phenomena associated with aging. It is recommended to start treatments with Gerovital H3, administered in injectable or oral form, from the age of over 40 - 50, respecting the indications of the medicine's package insert, the indications of the doctor supervising the therapy, but also the preferences of each patient. Of great importance is the long-term treatment, under periodic monitoring, as long as there are no adverse reactions or contraindications, as well as respecting some lifestyle recommendations.
Dr. Gabriela Cirstescu
Geriatrician specialist, Anti-Aging Clinic
www.gerovitalcosmetic.com
www.gerovital-h3.com
www.originalgerovital.blogspot.com
